Wyrostkiewicz Dorota, Skorupa Wojciech, Barańska Inga, Kuś Jan
I Klinika Chorób Płuc Instytutu Gruźlicy i Chorób Płuc, ul. Płocka 26, Warsaw.
Pneumonol Alergol Pol. 2013;81(5):453-9.
Rituximab (RTX) is a monoclonal antibody against the CD20 antigen found on the surface of B cells. RTX causes cell lysis and is therefore used to treat lymphomas, leukaemias, transplant rejection and certain autoimmune disorders. Pulmonary adverse events associated with RTX have been reported in literature. We describe a patient with follicular lymphoma treated with R-CHOP scheme (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) who had pulmonary symptoms during chemotherapy which were diagnosed as rituximab-induced interstitial pneumonia. Symptoms and radiological changes resolved with prednisone therapy.
